Transcript levels of inflammatory modulators in heart after LPS treatment
Transcript and genotype . | Copy no. × 104/100 ng by time after LPS . | . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|
. | 0 h . | 3 h . | 6 h . | 24 h . | 48 h . | ||||
TNFα | |||||||||
WT | ND | ND | 1.8 ± 0.4 | ND | ND | ||||
EPCRδ/δ | ND | 1.6 ± 0.9 | 1.2 ± 0.5 | ND | ND | ||||
IL1β | |||||||||
WT | ND | ND | 1.4 ± 0.4 | ND | ND | ||||
EPCRδ/δ | ND | ND | 1.1 ± 0.3 | ND | ND | ||||
IL6 | |||||||||
WT | ND | 21 ± 7 | 16 ± 4 | 1.4 ± 0.9 | ND | ||||
EPCRδ/δ | ND | 31 ± 7 | 14 ± 4 | 4.9 ± 4.4 | ND | ||||
MIP-2 | |||||||||
WT | ND | 2.9 ± 2.1 | 22 ± 1 | 2.7 ± 0.8 | 8.2 ± 4 | ||||
EPCRδ/δ | ND | 690 ± 21† | 620 ± 230† | 13 ± 6 | 15 ± 10 | ||||
MCP-1 | |||||||||
WT | ND | 140 ± 39 | 290 ± 110 | 37 ± 17 | 38 ± 13 | ||||
EPCRδ/δ | ND | 200 ± 40 | 200 ± 44 | 9.5 ± 3.3 | 21 ± 7 | ||||
iNOS | |||||||||
WT | ND | ND | 3.9 ± 1.0 | ND | ND | ||||
EPCRδ/δ | ND | 3.1 ± 2.1 | 3.9 ± 0.5 | ND | ND | ||||
HIF1α | |||||||||
WT | 11 ± 5 | 14 ± 5 | 75 ± 18 | 55 ± 18 | 42 ± 10 | ||||
EPCRδ/δ | 19 ± 5 | 48 ± 12† | 93 ± 14 | 35 ± 18 | 22 ± 6 | ||||
VEGF | |||||||||
WT | 15 ± 2 | 11 ± 2 | 20 ± 5 | 26 ± 9 | 24 ± 13 | ||||
EPCRδ/δ | 26 ± 7 | 44 ± 23 | 16 ± 3 | 13 ± 4 | 26 ± 7 |
Transcript and genotype . | Copy no. × 104/100 ng by time after LPS . | . | . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|
. | 0 h . | 3 h . | 6 h . | 24 h . | 48 h . | ||||
TNFα | |||||||||
WT | ND | ND | 1.8 ± 0.4 | ND | ND | ||||
EPCRδ/δ | ND | 1.6 ± 0.9 | 1.2 ± 0.5 | ND | ND | ||||
IL1β | |||||||||
WT | ND | ND | 1.4 ± 0.4 | ND | ND | ||||
EPCRδ/δ | ND | ND | 1.1 ± 0.3 | ND | ND | ||||
IL6 | |||||||||
WT | ND | 21 ± 7 | 16 ± 4 | 1.4 ± 0.9 | ND | ||||
EPCRδ/δ | ND | 31 ± 7 | 14 ± 4 | 4.9 ± 4.4 | ND | ||||
MIP-2 | |||||||||
WT | ND | 2.9 ± 2.1 | 22 ± 1 | 2.7 ± 0.8 | 8.2 ± 4 | ||||
EPCRδ/δ | ND | 690 ± 21† | 620 ± 230† | 13 ± 6 | 15 ± 10 | ||||
MCP-1 | |||||||||
WT | ND | 140 ± 39 | 290 ± 110 | 37 ± 17 | 38 ± 13 | ||||
EPCRδ/δ | ND | 200 ± 40 | 200 ± 44 | 9.5 ± 3.3 | 21 ± 7 | ||||
iNOS | |||||||||
WT | ND | ND | 3.9 ± 1.0 | ND | ND | ||||
EPCRδ/δ | ND | 3.1 ± 2.1 | 3.9 ± 0.5 | ND | ND | ||||
HIF1α | |||||||||
WT | 11 ± 5 | 14 ± 5 | 75 ± 18 | 55 ± 18 | 42 ± 10 | ||||
EPCRδ/δ | 19 ± 5 | 48 ± 12† | 93 ± 14 | 35 ± 18 | 22 ± 6 | ||||
VEGF | |||||||||
WT | 15 ± 2 | 11 ± 2 | 20 ± 5 | 26 ± 9 | 24 ± 13 | ||||
EPCRδ/δ | 26 ± 7 | 44 ± 23 | 16 ± 3 | 13 ± 4 | 26 ± 7 |
n = 7 to 11 mice for the various experiments.
*Transcript expression levels below 1.0 × 104 molecules/100 ng total RNA were considered not detectable (ND) in this method.
P < .05